RSS   Newsletter   Contact   Advertise with us
Post Online Media

Stellar Biotechnologies revenues $0.21 million

Share on Twitter Share on LinkedIn
Staff Writer |
Stellar Biotechnologies
Stellar Biotechnologies   Net loss was $5.04 million

Stellar Biotechnologies reported financial results for the fiscal year ended September 30, 2018.

Total revenues for fiscal year 2018 were $0.21 million compared to $0.23 million for the prior year. The change was due to a decrease in contract services revenue which was partially offset by an increase in product sales.

For fiscal year 2018, Stellar reported a net loss of $5.04 million, or $1.76 per basic share, compared to a net loss of $5.03 million, or $3.44 per basic share, for fiscal year 2017.

The weighted average number of shares used in the calculation of net loss per share for fiscal years 2018 and 2017 were 2,869,374 and 1,462,459, respectively.

At September 30, 2018, the company had working capital of $10.2 million. Cash, cash equivalents and short-term investments totaled $10.3 million.

What to read next
POST Online Media Contact